PDE4 Inhibitors in Treatment of Plaque Psoriasis

Neal Bhatia, MD, provides an overview of treatment options for patients with chronic plaque psoriasis, focusing specifically on the use of topical agents.

Neal Bhatia, MD, discusses patient adherence as one of the challenges with topical treatments in plaque psoriasis.

Neal Bhatia, MD, reviews roflumilast, a newly approved topical agent for plaque psoriasis treatment.

Neal Bhatia, MD, addresses concerns about the long-term use of topical treatments in plaque psoriasis.

Leon Kircik, MD, provides an overview of PDE4 inhibitors in the treatment of plaque psoriasis.

Leon Kircik, MD, discusses the recent FDA approval of roflumilast for plaque psoriasis treatment.

Leon Kircik, MD, reviews a recent study of roflumilast and its long-term efficacy and safety data in chronic plaque psoriasis.

Leon Kircik, MD, shares his impressions of the long-term data of roflumilast, and where it fits into clinical practice.

Neal Bhatia, MD, FAAD, discusses the current treatment landscape for patients with chronic plaque psoriasis, focusing specifically on PDE4 inhibitors.

Neal Bhatia, MD, FAAD, provides an overview of the efficacy and safety results of the DERMIS 1 and DERMIS 2 trials for chronic plaque psoriasis treatment.

Neal Bhatia, MD, FAAD, reviews the clinical implications of roflumilast, a newly approved topical agent for chronic plaque psoriasis treatment.